AG-490 (Tyrphostin B42)

Catalog No.S1143 Synonyms: Zinc02557947

AG-490 (Tyrphostin B42) Chemical Structure

Molecular Weight(MW): 294.30

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

Size Price Stock Quantity  
In DMSO USD 70 In stock
USD 50 In stock
USD 100 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Increased expression of VEGF and p-STAT3 induced by CXCL1 was blocked by either AG490 or SB225022 in AGS cells.

    Cancer Letters, 2015, 359(2): 335-43 . AG-490 (Tyrphostin B42) purchased from Selleck.

    Pre-treatment with AG490 and PD98059 alone or in combination leads to significant decrease in spheroid formation and number compared with PRL treatment alone.

    Carcinogenesis, 2014, 35(4): 795-806 . AG-490 (Tyrphostin B42) purchased from Selleck.

  • IL6 normally induces WASF3 expression in MDA231 cells, but co-treatments with AG490 (a pan-JAK inhibitor) show a dose-dependent reduction of both WASF3 levels and activated STAT3 levels.

    Carcinogenesis 2013 34, 1994-9. AG-490 (Tyrphostin B42) purchased from Selleck.

    Inhibition of JAK1/2 with AG490 or STAT3 with S3I-201 leads to reduced STAT3 activation and reduced WASF3 levels. In contrast, treatment with Dasatinib (SRC inhibitor) or Gefitinib (EGFR inhibitor) does not significantly affect activated STAT3 or WASF3 levels

    Carcinogenesis 2013 34, 1994-9. AG-490 (Tyrphostin B42) purchased from Selleck.

  • Prostate 2013 73(3), 267-77. AG-490 (Tyrphostin B42) purchased from Selleck.

    Biochem Biophys Res Commun 2013 435(4), 533-9. AG-490 (Tyrphostin B42) purchased from Selleck.

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Targets
EGFR [1]
(Cell-free assay)
0.1 μM
In vitro

AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. [1] Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. [2] AG-490 (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. [3] AG-490 potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. [4] Although AG-490 alone has no effect on proliferation of FDrv210H cells at a concentration of 5 μM, AG-490 can synergize with STI571 to enhance its inhibitory effect on p210bcr-abl driven proliferation. [5] AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. [6] AG-490 (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. [7] AG-490 at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. AG-490 also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. [8]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BC3 NE\iSm5HfW6ldHnvckBCe3OjeR?= NX7DbYZbOTBy4pEJxtVO MUeyOEBp MnTicYVlcWG2ZYOgVGVNKGOnbHygZZBweHSxc3nz NUTHOoV[OjZzOES5PVk>
BCBL1 MXvGeY5kfGmxbjDBd5NigQ>? MU[xNFDjiIoEtV2= M3e4V|I1KGh? NWC1VmI1dWWmaXH0[ZMhWEWOIHPlcIwh[XCxcITvd4l{ NGrX[JIzPjF6NEm5PS=>
BC3 MXvGeY5kfGmxbjDBd5NigQ>? NXy5ZndiOTBy4pEJxtVO NVzsNYZKOjRiaB?= NYTFNoZydWWmaXH0[ZMh\GVvcHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQ{KGOxcoLlcIF1\WRid3n0bEBJW1B5MDDhcoQhUFOIMTDy[YR2[3Srb36= MWiyOlE5PDl7OR?=
BCBL1 NVXoToxkTnWwY4Tpc44hSXO|YYm= M{TrW|ExOOLCidM1US=> NV3IW2w4OjRiaB?= NXOwTGNXdWWmaXH0[ZMh\GVvcHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQ{KGOxcoLlcIF1\WRid3n0bEBJW1B5MDDhcoQhUFOIMjDy[YR2[3Srb36= M2juO|I3OTh2OUm5
BC3 NV\sbXUyTnWwY4Tpc44hSXO|YYm= M330bFExOOLCidM1US=> NWXpc24xOjRiaB?= NHGy[2ZqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yCobIX4xsA> NY[0VpNxOjZzOES5PVk>
BCBL1 MWrGeY5kfGmxbjDBd5NigQ>? Mn3HNVAx6oDLwsXN M3XxNlI1KGh? M17Ifolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKG[udYlCpC=> NISyXHozPjF6NEm5PS=>
SK-MEL-28 M2nreWZ2dmO2aX;uJGF{e2G7 MWm1NE8yODEkgJpCuW0> NHnvdZA1QCCq M4j3cGROW09? MXvy[YR2[2W|IHHuc4lscXNicnXzbZN1[W6lZR?= M{DHV|I2OjF4NUKy
MeWo NXjodVJETnWwY4Tpc44hSXO|YYm= Mnq2OVAwOTBy4pEJxtVO M3vrOFQ5KGh? M320ZWROW09? MUPy[YR2[2W|IHHuc4lscXNicnXzbZN1[W6lZR?= MmHaNlUzOTZ3MkK=
SK-MEL-5 MoPZSpVv[3Srb36gRZN{[Xl? MnfzOVAwOTBy4pEJxtVO M3uwUlQ5KGh? NVjrdVBGTE2VTx?= Mnz1doVlfWOnczDhco9qc2m|IILld4l{fGGwY3W= MYKyOVIyPjV{Mh?=
SK-MEL-2 M1nFN2Z2dmO2aX;uJGF{e2G7 NFXnTVk2OC9zMEFihKnDvU1? M1;L[FQ5KGh? Ml65SG1UVw>? MVzy[YR2[2W|IHHuc4lscXNicnXzbZN1[W6lZR?= M2\3UFI2OjF4NUKy
B16-F0 MXzGeY5kfGmxbjDBd5NigQ>? NX73XZRtPTBxMUCw5qCKyrWP NFvrSJE1QCCq M3rDUWROW09? Mn3jdoVlfWOnczDhco9qc2m|IILld4l{fGGwY3W= M2TDWFI2OjF4NUKy
TRPM2/HEK  NG\W[HNHfW6ldHnvckBCe3OjeR?= M33NXFAvOeLCk{K1xsDDvU1? MnHVNVXDqG2rbh?= NUDkfGNDTE2VTx?= MoTRdoVlfWOnczDINm8zNWmwZIXj[YQhS2F{K3nuZ5Jm[XOnIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{LDDhcoQhfGinIFnDOVDDqH[jbIXlJJdieyBzLkhCpOK2VQ>? MoO0NlUyPzl3N{S=
U937  MkDQSpVv[3Srb36gRZN{[Xl? M3HqbVAvOeLCk{K1xsDDvU1? MWexOeKhdWmw M4\VSWROW09? MVTy[YR2[2W|IFiyU|IucW6mdXPl[EBE[TJtaX7jdoVie2ViaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJuIHHu[EB1cGViSVO1NOKhfmGudXWge4F{KDBwNNMgxtVO M2nEUFI2OTd7NUe0
TRPM2/HEK  NF;3cIJHfW6ldHnvckBCe3OjeR?= NVLHT5R4OTEEoNM1US=> NGHWS2Y1OMLibXnu M1[wdGROW09? NIHIeFZz\WS3Y3XzJHRTWE1{IHHjeIl3[XSrb36g[ZZmdiCjdDDobYdpKGOxbnPlcpRz[XSrb37zJI9nKEh{T{K= NHPR[40zPTF5OUW3OC=>
GL37  NVLTfnhoS2WubDDWbYFjcWyrdImgRZN{[Xl? MWmwMVExyqEEtV2= M3fib|Q5KGh? NVK1R|kze3WycILld5NmeyCOYTDlfJBz\XO|aX;u M4HFXlI1QTl7NkW3
NRK-52E MWPGeY5kfGmxbjDBd5NigQ>? NXvNUYQ{OcLiwsXN M4DLcFExKG2rbh?= M1rkWYJtd2OtczD0bIUhe3SrbYXsZZRwenliZX\m[YN1KG:oIFHu[{BKUSCxbjDQZZguOiCneIDy[ZN{cW:wwrC= MWOyOFcyODR{Mx?=
NRK-52E MVHGeY5kfGmxbjDBd5NigQ>? NIfZ[2oyyqEEtV2= MVmxNEBucW5? Mo\FZoxw[2u|IFHu[{BKUSCrbnT1Z4VlKEOGMkSg[ZhxemW|c3nvci=> NVHtWWlnOjR5MUC0NlM>
HSC  NUDlTHR2TnWwY4Tpc44hSXO|YYm= M3\DZVIxKM7:TR?= Mon3NUBp M4m1fYFjem:pYYTld{B1cGViZHnm[oVz\W62aXHsJIVn\mWldIOgc4YhdGWydHnuJI9zKEGJRYO= M1zGPVI1PjF2MUm5
EJ NHjVdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[5OlUxNzhyIN88US=> NHjYbmczPC92OD:3NkBp NIrM[YJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MnrrNlQ2QDdyNEm=
EJ NXfrO29uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL5dW9CPTBxOECg{txO NICzZlk1QCCq M3zZd4NifXOnczDTMZBp[XOnIHHydoV{fA>? MWOyOFU5PzB2OR?=
EJ Mkn6SpVv[3Srb36gRZN{[Xl? MVW1NE85OCEQvF2= MmW1OFghcA>? NVmyOpF5\G:5boLl[5Vt[XSnczDjMW16[yxiY4njcIlvTDFuIIP1dpZqfmmwIHHu[EBXTUeIIHX4dJJme3Orb37z MmfCNlQ2QDdyNEm=
HepG2 NUn3THExTnWwY4Tpc44hSXO|YYm= M132WlUxNTVyMDFOwG0> NW[4[YI1PjEEoH3pci=> M2HxcolvcGmkaYTzJJRp\SCLTD22MYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIDjUfZI4ODVrIHHu[EBUXEGWMzCoWJlzPzB3KTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHXh[GozPDJ2MkC0Oi=>
SGC7901 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUGwMVExOCEQvF2= MlzPNlQwPDhxN{KgbC=> M1rVdoNifXOnczDhJJNq\26rZnnjZY51KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCmb4PlMYRmeGWwZHXueIx6KGK3dDDuc5QhfGmvZT3k[ZBmdmSnboTsfS=> MVqyOFE2OTJ3NR?=
AGS  MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M12wbFAuOTByIN88US=> M1jBcFI1NzR6L{eyJIg> NYjoc4E2[2G3c3XzJIEhe2mpbnnmbYNidnRicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHTvd4Uu\GWyZX7k[Y51dHliYoX0JI5wfCC2aX3lMYRmeGWwZHXueIx6 NHfkXVEzPDF3MUK1OS=>
SGC7901 M{DxZ2Z2dmO2aX;uJGF{e2G7 MUO1NEDPxE1? Ml;1NlQwPDhxN{KgbC=> NVXFW|dsfGinIHzleoVteyCxZjDwTmFMOiCkZXfhckB1dyCmZXPsbY5mKGG2IEK0JIhzNCCjbnSgdoVjd3WwZHXkJIF1KDd{IHjyxsA> NVf1NYdIOjRzNUGyOVU>
AGS  NX7ueVF[TnWwY4Tpc44hSXO|YYm= MX21NEDPxE1? M{fHOVI1NzR6L{eyJIg> MVH0bIUhdGW4ZXzzJI9nKHCMQVuyJIJm\2GwIITvJIRm[2yrbnWgZZQhOjRiaIKsJIFv\CC{ZXLveY5l\WRiYYSgO|IhcHMEoB?= NY\6N5RvOjRzNUGyOVU>
SGC7901 NUfFdng6TnWwY4Tpc44hSXO|YYm= M4TXXVUxKM7:TR?= MV6yOE81QC95MjDo NWfrRnRyfGinIHP5eI9xdGG|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC|dHHyeIVlKHSxIILlZo92dmRiYYSgO|IhcHJ? MWGyOFE2OTJ3NR?=
AGS  MoTESpVv[3Srb36gRZN{[Xl? MnXTOVAh|ryP MVeyOE81QC95MjDo MYL0bIUh[3m2b4DsZZNucWNibH;jZYxqgmG2aX;uJI9nKHCMQVuyJEhLSUt{IIDoc5NxcG:{eXzheIVlKGG2IILld4llfWW|IGT5dlExODdiYX7kJHR6ejFyMEipJIRm[3KnYYPl[EBi\nSncjDBS|Q6OCC2cnXheI1mdnRiZn;yJFI1KGGwZDC0PEBpeixiYoX0JJN1[XK2ZXSgeI8hemWkb4Xu[EBifCB5MjDodi=> NVHnNlNlOjRzNUGyOVU>
MC3T3-E1  NHPpbJRHfW6ldHnvckBCe3OjeR?= M4fNW|UxKM7:TR?= NEWxUFk1KGh? MnWzbY5pcWKrdIOgTHNGNWmwZIXj[YQhSk2SNzDhcoQhT0iUIIDyc5RmcW5iZYjwdoV{e2mxbtMg M1\FbVI{QDd5N{O0
7TD1-DXM MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2xNEDPxE1? M{POO|czKGh? MkfWSG1UVw>? M1nXZ4lvcGmkaYTzJINmdGxiZ4Lve5Rp M2Sx[FI{QDdzMUW5
7TD1-WD-90 NYq2c3A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37nNlExKM7:TR?= MWi3NkBp NYnWWphFTE2VTx?= NHXtWXVqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NELId4MzOzh5MUG1PS=>
7TD1-DXM MlXJRZBweHSxc3nzJGF{e2G7 M2D2OVUxKM7:TR?= MnrYOFghcA>? NYXmXG84TE2VTx?= M{LLdolv\HWlZYOgZZBweHSxc3nz MmTNNlM5PzFzNUm=
7TD1-WD-90 NXz0SmlvSXCxcITvd4l{KEG|c3H5 M2PCZ|UxKM7:TR?= MVi0PEBp NVPVRWxHTE2VTx?= MUnpcoR2[2W|IHHwc5B1d3Orcx?= NVnYd4N[OjN6N{GxOVk>
7TD1-WD-90  Mm\aSpVv[3Srb36gRZN{[Xl? NH;TVFQ2OCEQvF2= Mnu0OkBp MnvvSG1UVw>? MnnJd4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGpCUzJiYX7kJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMx?= NWnnW5NNOjN6N{GxOVk>
HepG2  NVf4OXA5TnWwY4Tpc44hSXO|YYm= NULzSW1HOTByIN88US=> M1P0T|EzNzJ2IHi= M4HiUIlvcGmkaYTzJHNVSVR|IIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdg>? NX3xRnZSOjN6M{[0NFA>
RAW264.7  MoXZSpVv[3Srb36gRZN{[Xl? M2TWdFUxyqEQvF5CpC=> NIXTS4UzPC92ODDo NY\YPHhSe3WycILld5NmeyCUQV7LUE1qdmS3Y3XkJI9{fGWxY3zhd5Rw\2WwZYPpdy=> NUjPd5R[OjN4NkWwNVg>
RAW264.7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTlNE02OMLizszNxsA> NWizTmJzPDkEoHi= M3HNcolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wt[IVx\W6mZX70cJk> M3:y[|I{PjZ3MEG4
RAW264.7 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfxU3cxNTVywrFOwG3DqA>? NF;vfWc1QMLiaB?= NY\vbWFR[2G3c3XzJIFvKGG{cnXzeEBw\iCUQWeyOlQvPyClZXzsd{BifCC2aHWgS|AwTzFicHjhd4Uhd2ZidHjlJINmdGxiY4njcIU> M4n2UFI{PjZ3MEG4
RAW264.7 MmnISpVv[3Srb36gRZN{[Xl? MWi1NOKh|ryP M4PUcFI1NzR6IHi= NV\SVnRZcW6qaXLpeJMhWkGQS1ytbY5lfWOnZDDOSmFV[zFiZYjwdoV{e2mxbjDhcoQheGixc4Doc5J6dGG2aX;uJI9nKFOnckeyO3NVSVR| M2PGelI{PjZ3MEG4
A549  NH7SZlZHfW6ldHnvckBCe3OjeR?= NWH6VI5UOjBxNECg{txO NV31UYRkOjBiaB?= Mn;rNlAh|ryPIFHHOFkxKHO3cIDy[ZN{\XNidHjlJJJi\GmjdHnvck1qdmS3Y3XkJIlvfmG|aX;uJI9nKEF3NEmgZ4VtdHN? M1P6c|I{PjJyMUmx
A549  MXrGeY5kfGmxbjDBd5NigQ>? NIfuVogyOC9{MD:0NEDPxE1? MoLUNlQhcA>? NF3lXVZ{fXCycnXzd4V{KHSqZTDyZYRq[XSrb36tbY5lfWOnZDDlcIV3[XSrb36gc4YhXkWJRtMg MUeyN|YzODF7MR?=
HUVECs NGrsSm9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mo\VNlAhyrWP NE[yd3Q1KGh? NISyOZRifHSnboXheIV{KEh{T{KtbY5lfWOnZDDj[YxtKHOqcnnub4Fo\SCjbnSgbY1xem:4ZXSgeIhmKGG2dHHjbI1mdnRicnH0[UBw\iC2aHWgZ4VtdHN? NYnxcmRFOjN2OEO5OFY>
HUVECs NXfRSFA4SXCxcITvd4l{KEG|c3H5 NE\CeowzOCEEtV2= MoHWOEBp M4fEfpNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBk\WyuIHHwc5B1d3SrYzDpcoRmgA>? MmLGNlM1QDN7NE[=
BV-2  M2fwPWZ2dmO2aX;uJGF{e2G7 MWCyNEDDvU1? MX2xOkBp MnTTbY5pcWKrdIOgUHBUNWmwZIXj[YQhW1SDVEGgdIhwe3Cqb4L5cIF1cW:wIIfpeIgh[Wyvb4P0JINwdXCuZYTlcJkh\GmvaX7pd4hm\CCrTl;TJIV5eHKnc4Ppc44> MWCyN|I{PjN5MB?=
NRK-52E  NUniN41UTnWwY4Tpc44hSXO|YYm= MVy1xsDPxE1? NHzle3k{OMLibXnu NWHOVWtE[XS2ZX71ZZRmeyCDbnetLFHjiJN5KT3pcohq[mm2ZXSgWGdHNc7{MTDtVm5CKGG2IEG2xsBpyqB? M4T5T|I{OTd2N{W3
SW620  NInHSVBHfW6ldHnvckBCe3OjeR?= NWjZOI5VOjBiwsXN MV6xM|YhcA>? Mn;NbY5pcWKrdIOgdE1UXEGWMzDhZ5RqfmG2aX;u MYeyN|EyODZ{NR?=
RPE  NXzse2xxTnWwY4Tpc44hSXO|YYm= NGPLc|k{OCEEtV5CpC=> NWe1WoRUOyCq M1mweolvcGmkaYTzJJRp\SCrbnT1Z5Rqd25ib3[gdE1UXEGWMzDlfJBz\XO|aX;u NYnvV49FOjNyOUSwOlc>
SW1116 MnfsSpVv[3Srb36gRZN{[Xl? NUTNe41kOTByINM1UeKh MUCyOE81QC95MjDo NWPpT4lq\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEqDS{KgZY5lKHCMQVuyJJRqdWVvZHXw[Y5l\W62bIm= NG\CeYYzOjB3MEe5NC=>
HT29 MlrXSpVv[3Srb36gRZN{[Xl? Mo\YNVAxKML3TdMg NVXsN3NUOjRxNEivO|IhcA>? NWHXXJZp\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEqDS{KgZY5lKHCMQVuyJJRqdWVvZHXw[Y5l\W62bIm= Mor1NlIxPTB5OUC=
SW1116 MmizSpVv[3Srb36gRZN{[Xl? MoWyNVAxKML3TdMg NHq3RVEzPC92OD:3NkBp NWW3WGEy\GWlcnXhd4V{KHSqZTDwV3RCXDNibHX2[Yx{KGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB? MXyyNlA2ODd7MB?=
HT29 MnLvSpVv[3Srb36gRZN{[Xl? M{PlU|ExOCEEtV5CpC=> NGfsemMzPC92OD:3NkBp MUPk[YNz\WG|ZYOgeIhmKHCVVFHUN{Bt\X[nbIOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> NWLUfWFPOjJyNUC3PVA>
ARPE-19 NI[3dIZHfW6ldHnvckBCe3OjeR?= NFi0dlM2yqEQvF2= NUP3N2hqOzEEoH3pci=> M1j0dYlvcGmkaYTzJGpCUzJicHjvd5Bpd3KrbHH0bY9v NHvjcYQzOTZ{MEm2Ny=>
HSC-T6 M3H6dmFxd3C2b4Ppd{BCe3OjeR?= M{TDNFExyqEQvF2= NYrVRmhEOsLiaNMg NWDrNWpkcW6qaXLpeJMhfGinIHHwc5B1d3OrczDv[kBJW0NvVE[gZ4VtdHNiaX7keYNm\CCkeTDDSGU> M2f4[lIyOzl4OUm4
HSC-T6 MmfxSpVv[3Srb36gRZN{[Xl? M17abFExyqEQvF2= NV;1TJlWOsLiaNMg MknmbY5pcWKrdIOgeIhmKGW6cILld5Nqd26|IH;mJJB[NVOWQWSxJIFv\CCEYXSgbY5lfWOnZDDifUBETEV? M1\NZVIyOzl4OUm4
Hep-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYeyOU0yODBizszN M1P4dVI1NzR6L{eyJIg> NIHnZWVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NYjC[HRNOjF|MEm0PFE>
Hep-2 NIrsVmRCeG:ydH;zbZMhSXO|YYm= MYK1NEDPxE1? M33TPFI1NzR6L{eyJIg> NU\zR2R4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7 NWTUfY1ZOjF|MEm0PFE>
Hep-2 M2jQWGZ2dmO2aX;uJGF{e2G7 NYjaeHhsPTBizszN M4rNRVI1NzR6L{eyJIg> NXrXOI4ycW6qaXLpeJMhTzFidH:gV{Bk\WyuIHP5Z4xmKHS{YX7zbZRqd25iYX7kJIlv\HWlZYOgS|Eh[2WubDDjfYNt\SCjcoLld5Q> NF;nRlczOTNyOUS4NS=>
Hep-2 MVTGeY5kfGmxbjDBd5NigQ>? NILNd4c2OCEQvF2= MkixNlQwPDhxN{KgbC=> NIG4d5dld3ewcnXneYxifGW|IITo[UBUXEGWMzygdE1UXEGWMzDhcoQhe3W{dnn2bY4heHKxdHXpckBt\X[nbIO= NIrOVI0zOTNyOUS4NS=>
KF8 M2TiUGZ2dmO2aX;uJGF{e2G7 MnzCNVDDqM7:TdMg MUixxsBp MkDzSG1UV8Li NXjYbo1tcW6qaXLpeJMhUUxvM{OtbY5lfWOnZDDOSk3PwkJiYXP0bZZifGmxbh?= NHXV[m8zODl2MEC0OS=>
KF8 NW\vemUxTnWwY4Tpc44hSXO|YYm= MWCxNOKh|ryPwrC= NUfxfo1sOcLiaNMg M{HCfWROW00EoB?= NVPUd3BtcW6qaXLpeJMhUUxvM{OtbY5lfWOnZDDJ{tpD|rFiZHXndoFl[XSrb36gZY5lKE6ILd86RkBi[3SrdnH0bY9v MkL2NlA6PDByNEW=
HEL  MnPJSpVv[3Srb36gRZN{[Xl? MnPINVAxyqEQvF2= MmHwNVIuPzJiaB?= MUHpcohq[mm2czD0bIUhdGW4ZXygc4YheC2MQVuyMEBLSUt{ Mn[2NlA3OjFyNkG=
HEL MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XCVFExOMLizszN NEfLO3MxNTViZB?= M1jlXpJm\HWlZYOg[5Jwf3SqIH;mJGpCUzKYNkG3Sk1mgHC{ZYPzbY5oKEiHTDDj[Yxtew>? NWLORlRrOjB4MkGwOlE>
A-172 NHfx[5RHfW6ldHnvckBCe3OjeR?= M1zmVlUxNzFyMNMg{txO NVXOO4hLPDhiaB?= M2XtOJJm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NETsSogzODV6OUWyOS=>
MZ-18 NHv1VY1HfW6ldHnvckBCe3OjeR?= MYe1NE8yODEEoN88US=> MU[0PEBp M2nMeZJm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NEO3WZIzODV6OUWyOS=>
MZ-54 NH;3cGFHfW6ldHnvckBCe3OjeR?= NGfQd3Y2OC9zMEFCpO69VQ>? MonFOFghcA>? MmjldoVlfWOnczD0bIUhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBUXEGWMzDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NX\KOpRQOjB3OEm1NlU>
MZ-256 M2i4bWZ2dmO2aX;uJGF{e2G7 NE\HR3A2OC9zMEFCpO69VQ>? M{\yblQ5KGh? M2H2N5Jm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> Mm[yNlA2QDl3MkW=
MZ-304 MmqwSpVv[3Srb36gRZN{[Xl? MWO1NE8yODEEoN88US=> NF;QO3g1QCCq M{TrO5Jm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> M4XYOFIxPTh7NUK1
A-172 NIXmS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e5fFUxNzFyMNMg{txO MkjCOFghcA>? NGH1PItt\WGmczD0c{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQhemWmdXP0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDveoVzKGFidHnt[UBx\XKrb3Sgc4YhPDkEoHi= M3rMS|IxPTh7NUK1
MZ-18 M{f5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXnOVAwOTBywrFOwG0> NGTjW2g1QCCq Mo\5cIVi\HNidH:gZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JJJm\HWldHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25ib4\ldkBiKHSrbXWgdIVzcW:mIH;mJFQ5yqCq MWGyNFU5QTV{NR?=
MZ-54 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK1NE8yODEEoN88US=> NFy4TI41QCCq MoLhcIVi\HNidH:gZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JJJm\HWldHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25ib4\ldkBiKHSrbXWgdIVzcW:mIH;mJFQ5yqCq MYiyNFU5QTV{NR?=
MZ-256 M3jLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi1NE8yODEEoN88US=> MlP0OFghcA>? MnPmcIVi\HNidH:gZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JJJm\HWldHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25ib4\ldkBiKHSrbXWgdIVzcW:mIH;mJFQ5yqCq MVGyNFU5QTV{NR?=
MZ-304 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvwfoRVPTBxMUCwxsDPxE1? MYe0PEBp MULs[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh? NH\PNFIzODV6OUWyOS=>
A-172 M3z5e2Z2dmO2aX;uJGF{e2G7 MVi1NE8yODEEoN88US=> NILZ[lI1QCCq M32zPIlvcGmkaYTzJI1q\3KjdHnvci=> MUOyNFU5QTV{NR?=
MZ-18 MWTGeY5kfGmxbjDBd5NigQ>? M2LsTFUxNzFyMNMg{txO M4jlWFQ5KGh? MX;pcohq[mm2czDtbYdz[XSrb36= MorCNlA2QDl3MkW=
MZ-54 MYLGeY5kfGmxbjDBd5NigQ>? NWrKO3BRPTBxMUCwxsDPxE1? MVK0PEBp NHjXPHpqdmirYnn0d{BucWe{YYTpc44> M2rENFIxPTh7NUK1
MZ-256 MUDGeY5kfGmxbjDBd5NigQ>? NWrY[Y56PTBxMUCwxsDPxE1? NIftS4w1QCCq MmKybY5pcWKrdIOgcYloemG2aX;u MX:yNFU5QTV{NR?=
MZ-304 M{HWdmZ2dmO2aX;uJGF{e2G7 MUm1NE8yODEEoN88US=> MXS0PEBp M2\zb4lvcGmkaYTzJI1q\3KjdHnvci=> NWjsXXJXOjB3OEm1NlU>
A-172 MmDFSpVv[3Srb36gRZN{[Xl? MW[xNFDDqM7:TR?= M1nSSVQ5KGh? NYjHXY1jcW6qaXLpeJMhcW64YYPpc44> M3rwVlIxPTh7NUK1
MZ-18 M3fiZWZ2dmO2aX;uJGF{e2G7 NFnEW3cyODEEoN88US=> MWO0PEBp M4fFeIlvcGmkaYTzJIlvfmG|aX;u M13yclIxPTh7NUK1
MZ-54 Mly1SpVv[3Srb36gRZN{[Xl? NHP5NJAyODEEoN88US=> M2THVlQ5KGh? NH3lUpdqdmirYnn0d{Bqdn[jc3nvci=> MnOwNlA2QDl3MkW=
MZ-256 NUfFXGg2TnWwY4Tpc44hSXO|YYm= MoOxNVAxyqEQvF2= MUW0PEBp M4nub4lvcGmkaYTzJIlvfmG|aX;u MkXsNlA2QDl3MkW=
MZ-304 NX7EbFdPTnWwY4Tpc44hSXO|YYm= NYjReJl5OTBywrFOwG0> MUO0PEBp NIjkbXVqdmirYnn0d{Bqdn[jc3nvci=> NUe1XHBJOjB3OEm1NlU>
A-172 MlGwSpVv[3Srb36gRZN{[Xl? NWPsdIJSPTBxMUCwxsDPxE1? M{\kclQ5KGh? NF\4[5Bz\WS3Y3XzJJRz[W6|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{ NXjBNXdUOjB3OEm1NlU>
MZ-18 NXXvfXZMTnWwY4Tpc44hSXO|YYm= NUDKS4dUPTBxMUCwxsDPxE1? MljTOFghcA>? MYLy[YR2[2W|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz NFvve|EzODV6OUWyOS=>
MZ-54 NV3SUId7TnWwY4Tpc44hSXO|YYm= MVq1NE8yODEEoN88US=> MoW4OFghcA>? NF3NboRz\WS3Y3XzJJRz[W6|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{ MWmyNFU5QTV{NR?=
MZ-256 MlTPSpVv[3Srb36gRZN{[Xl? NI\qV2o2OC9zMEFCpO69VQ>? MoD2OFghcA>? NY[1RotvemWmdXPld{B1emGwc3PybZB1cW:wIH;mJG1OWCCpZX7ld{BidmRicnXkeYNmeyCnbor5cYF1cWNiYXP0bZZqfHlib3[gUW1Rew>? NXnzc2I6OjB3OEm1NlU>
MZ-304 NFjqcVFHfW6ldHnvckBCe3OjeR?= MWK1NE8yODEEoN88US=> MW[0PEBp MX3y[YR2[2W|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz NVvObVM6OjB3OEm1NlU>
SW1990 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHIRnB6OjBizszN MX:yOE81QC95MjDo NYXzZYxLcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? Mk\JNlA1QDJ6NUi=
SW1990 MWrGeY5kfGmxbjDBd5NigQ>? NWfPeZdqOjBizszN MUCyOEBp NIrKU5Vl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVU2SLUKgZY5lKF[HR1[gcXJPSXN? M3fGelIxPDh{OEW4
SW1990 MWPGeY5kfGmxbjDBd5NigQ>? NG\W[2IzOCEQvF2= NUW4bWxrOjRiaB?= NXXQZ|A{\GWlcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YheC2VdHH0N{BmgHC{ZYPzbY9v NGDaSmMzODR6Mki1PC=>
SW1990 MWrJcpZie2mxbjDBd5NigQ>? MU[yNEDPxE1? MkPxNlQhcA>? M2TacJJm\HWlZYOgbY53[XOrb36gc4YhW1dzOUmwJINmdGy|wrC= MXWyNFQ5Ojh3OB?=
THP1 MWHGeY5kfGmxbjDBd5NigQ>? NGTvOZUyOCC3TR?= NGXGOpE{OCCvaX9CpC=> NVKzSXlbcW6qaXLpeJMhW1SDVEOgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wIHL5JI93\XJiNkCl MoDPNlA{QTN4OUC=
BMMC Mk\mSpVv[3Srb36gRZN{[Xl? MlW3NE0yOCEQvF2= NE\qOosyPcLibXnu M1;2NIlvcGmkaYTzJGxVSzUEoILlcIVie2ViaX6gZUBld3OnLXTldIVv\GWwdDDmZZNpcW:wIIfpeIghdmWjcjDjc41xdGW2ZTDpcohq[mm2aX;uJIF1KGOxbnPlcpRz[XSrb37zJQKqxjFywrFOwG0> NXTn[4xbOTl6M{W4OFU>
A549 MXvGeY5kfGmxbjDBd5NigQ>? NXLw[Fl2OTVizszt Mn\DNUBp NFnUU4FqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKG:wIIT5do9{cW6nIEewNUB4[XNiZHX0[YN1\WRiMUWgcYlvKGGodHXyJHNRTSCEIITy[YF1dWWwdB?= NE\Le24yQThyMU[2OS=>
OVCAR-3 NILxVW9HfW6ldHnvckBCe3OjeR?= MUGxNEB2VQ>? NFr4N3gyKGh? MlzabY5pcWKrdIOgUHBCNWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w NXvTW281OTl4NEezOlM>
PA-1 NHLON|hHfW6ldHnvckBCe3OjeR?= NVrWNpZLOTBidV2= MkDvNUBp NEnLZZFqdmirYnn0d{BNWEFvaX7keYNm\CCVVFHUN{BxcG:|cHjvdplt[XSrb36= M1izOlE6PjR5M{[z
OVCAR-3 NFW5Z2tHfW6ldHnvckBCe3OjeR?= NEOwPXkyOCC3TR?= MkjhNUBp MmXMbY5pcWKrdIOgJGxRSS2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxibX;0bYxqfHl? MXmxPVY1PzN4Mx?=
PA-1 MkX4SpVv[3Srb36gRZN{[Xl? MmiyNVAhfU1? NVjwVlNGOSCq M3zTbIlvcGmkaYTzJEBNWEFvaX7keYNm\CCxdnHybYFvKGOjbnPldkBk\WyuIH3veIltcXS7 MoDXNVk3PDd|NkO=
Jurkat  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{exb|UxKM7:TR?= MkDYNlQwPDhxN{KgbC=> MX;lcohidmOnczDUVmFKVC2rbnT1Z4V{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36= MlSyNVk2PjR6OUG=
SUPT1  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfZTVExPTBizszN MUSyOE81QC95MjDo Mmfy[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIdzd3e2aDDpcohq[mm2aX;u NWTvRZE2OTl3NkS4PVE>
Jurkat  NIPkN|NCeG:ydH;zbZMhSXO|YYm= MnK0OVAh|ryP MkDUNlQwPDhiaB?= MXrlcohidmOnczDUVmFKVC2rbnT1Z4V{KGOnbHygZZBweHSxc3nz MmPVNVk2PjR6OUG=
SUPT1  MW\BdI9xfG:|aYOgRZN{[Xl? M{LYR|UxKM7:TR?= MWSyOE81QCCq M3:0WoVvcGGwY3XzJHRTSUmOLXnu[JVk\XNiY3XscEBieG:ydH;zbZM> M1TVTVE6PTZ2OEmx

... Click to View More Cell Line Experimental Data

In vivo Administration of AG-490 drastically reduces the numbers of CD45+ and HLA-DR+ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. [2] In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. [6] Consistent with the in vitro blocking of JAK2 V617F mutant activity, AG-490 treatment at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. [8] Combined therapy with AG-490 and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. [6]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase autophosphorylation:

AG-490 is dissolved in DMSO 10%-H2O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M8Ac2, 2 mM MnCl2, 1 mM NaVO3, 1 μM ATP, and 1 μCi[γ-32P]ATP, final concentrations) and increasing concentrations of AG-490 (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of AG-490 (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
Cell Research:

[2]

+ Expand
  • Cell lines: Pre-B ALL
  • Concentrations: Dissolved in DMSO, final concentrations ~ 50 μM
  • Incubation Time: 16 hours
  • Method:

    Cells are exposed to different concentrations of AG-490 for 16 hours. For the determination of cell proliferation, [3H]tymidine (1 μCi) is added 6 hours or more before the cultures are terminated. Cells are then collected and samples counted in a liquid scintillation counter.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: SCID mice intravenously injected with ALL cells
  • Formulation: Dissolved in DMSO
  • Dosages: 0.85 mg + 0.5 mg daily
  • Administration: Continuous pump infusion supplemented with daily intraperitoneal injections
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 58 mg/mL (197.07 mM)
Ethanol 6 mg/mL (20.38 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 294.30
Formula

C17H14N2O3

CAS No. 133550-30-8
Storage powder
in solvent
Synonyms Zinc02557947

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to know whether AG490 (S1143) goes to CNS through BBB, or not?

  • Answer:

    AG-490 can go through the BBB. You can see this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Tags: buy AG-490 (Tyrphostin B42) | AG-490 (Tyrphostin B42) supplier | purchase AG-490 (Tyrphostin B42) | AG-490 (Tyrphostin B42) cost | AG-490 (Tyrphostin B42) manufacturer | order AG-490 (Tyrphostin B42) | AG-490 (Tyrphostin B42) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID